zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2025-22-3-01zdor-2870Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESКардиоренальный синдром: вопросы патогенеза и ранней диагностикиCardiorenal syndrome: issues of pathogenesis and diagnosishttps://orcid.org/0009-0009-5173-2328ЖогольП. Л.ZhogolP. L.

Жоголь Полина Леонидовна - ассистент кафедры внутренних болезней № 1 с курсами эндокринологии и гематологии.

Гомель

Polina L. Zhogol - Assistant at the Department of Internal Diseases No. 1 with the courses of Endocrinology and Hematology.

Gomel

polina-zhogol@mail.ruhttps://orcid.org/0000-0003-1051-0787МалаеваЕ. Г.MalaevaE. G.

Малаева Екатерина Геннадьевна - к.м.н., доцент, заведующий кафедрой внутренних болезней № 1 с курсами эндокринологии и гематологии.

Гомель

Ekaterina G. Malaeva - Candidate of Medical Sciences, Associate Professor, Head of the Department of Internal Diseases No. 1 with the courses of Endocrinology and Hematology.

Gomel

dr-malaeva@mail.ruhttps://orcid.org/0009-0000-5159-3473ШпаковскаяА. Г.ShpakovskayaA. G.

Шпаковская Анастасия Геннадьевна - врач-терапевт отделения профилактики № ٢.

Гомель

Anastasia G. Shpakovskaya - General Physician at the Prevention Department No. 2.

Gomel

anastasiva.2012@mail.ruhttps://orcid.org/0009-0002-6967-6589ДемьяненкоИ. Н.DemyanenkoI. N.

Демьяненко Илона Николаевна - заведующий приемным отделением.

Гомель

Ilona N. Demyanenko - Head of the Emergency Room.

Gomel

ilona_Demyanenko@mail.ruhttps://orcid.org/0009-0009-8161-8331МининА. В.MininA. V.

Минин Артём Витальевич - врач-терапевт приемного отделения.

Гомель

Artem V. Minin - General Physician at the Emergency Room.

Gomel

artemminin28091996@gmail.comhttps://orcid.org/0009-0008-2243-2097ГладковскийП. Н.GladkovskyP. N.

Гладковский Павел Николаевич - заместитель главного врача по организационно-методической и идеологической работе.

Гомель

Pavel N. Gladkovsky - Deputy Chief Physician for Organizational, Methodological and Ideological Work.

Gomel

pashvash@mail.ruhttps://orcid.org/0009-0005-5272-825XАнтановичД. Ю.AntanovichD. Y.

Антанович Денис Юрьевич - врач-терапевт приемного отделения.

Гомель

Denis Y. Antanovich - General Physician at the Emergency Room.

Gomel

antanowichd@gmail.comГомельский государственный медицинский университетGomel State Medical UniversityПоликлиника № 7Polyclinic No. 7Гомельская городская клиническая больница скорой медицинской помощиGomel City Clinical Emergency Hospital202527092025223714Copyright © Жоголь П.Л., Малаева Е.Г., Шпаковская А.Г., Демьяненко И.Н., Минин А.В., Гладковский П.Н., Антанович Д.Ю., 20252025Жоголь П.Л., Малаева Е.Г., Шпаковская А.Г., Демьяненко И.Н., Минин А.В., Гладковский П.Н., Антанович Д.Ю.Zhogol P.L., Malaeva E.G., Shpakovskaya A.G., Demyanenko I.N., Minin A.V., Gladkovsky P.N., Antanovich D.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/2870

Сочетанное проявление нарушений в организме человека со стороны функционирования таких жизненно важных органов, как сердце и почки, с развитием и прогрессированием сопутствующих гемодинамических расстройств имеет название «кардиоренальный синдром» (КРС). В начале исследований КРС первично возникшая симптоматика недостаточности со стороны сердечно-сосудистой системы с последующим развитием нарушений функции почек считалась основным патофизиологическим компонентом. На текущем этапе изучения данного синдрома имеется большее представление о механизмах его развития, однако существуют и недостаточно изученные аспекты, так как многочисленные системы организма человека способны повлиять на его возникновение и течение.

Настоящий обзор направлен на анализ научных публикаций, освещающих изученные этиологические факторы, патофизиологические механизмы и патогенез КРС 2 типа, а также актуальные вопросы диагностики и терапии хронической болезни почек (ХБП), ассоциированной с хронической сердечной недостаточностью (ХСН).

Цель настоящего обзора — анализ современных данных о патогенетических механизмах, диагностических подходах и терапевтических стратегиях при КРС 2 типа, с акцентом на перспективные биомаркеры раннего выявления и новые методы лечения.

Обзор литературы строился на следующих принципах:

Период анализа литературы охватывает публикации за 2018–2023 гг. с включением ключевых более ранних работ, имеющих фундаментальное значение для понимания патогенеза. Особое внимание уделено исследованиям, проводимым в период 2020–2023 гг., отражающим современные достижения в диагностике и лечении.

The combined disorders in a human’s body related to functioning of such vital organs as heart and kidney with development and progress of concomitant hemodynamic disorders is called as cardiorenal syndrome. In early studies, insufficient cardiac pump function with subsequent renal dysfunction was considered as the main pathophysiologic component of cardiorenal syndrome. At the current stage of studying this syndrome, there is a greater understanding of the mechanisms of its development, however, there are also insufficiently studied aspects, since multiple systems of the human body can influence its occurrence and course.

This review aims to analyze scientific publications covering the studied etiological factors, pathophysiological mechanisms, and pathogenesis of type 2 cardiorenal syndrome, as well as current issues in diagnosis and treatment of chronic kidney disease associated with chronic heart failure.

The objective of the review is to analyze current data on pathogenetic mechanisms, diagnostic approaches and treatment strategies for type 2 cardiorenal syndrome, focusing on novel biomarkers and therapeutic methods.

The literature review was conducted according to:

The analysis covers publications from 2018-2023, including some seminal earlier works that have fundamental importance for understanding of pathogenesis. Special attention was given to studies conducted for the period of 2020-2023 and reflecting modern diagnostic and therapeutic advances.

кардиоренальный синдромхроническая сердечная недостаточностьхроническая болезнь почекпатогенезбиомаркерыcardiorenal syndromechronic heart failurechronic kidney diseasepathogenesisbiomarkersОтсутствуютNoneReferencesCardio-Renal Connections in Heart Failure and Cardiovascular, 2019. [Electroniic resource] National Heart, Lung, and Blood Institute. [date of access 2024 October 13]. Available from: https://www.nhlbi.nih.gov/events/2004/cardio-renal-connections-heart-failure-and-cardiovascular-diseasejCardio-Renal Connections in Heart Failure and Cardiovascular, 2019. [Electroniic resource] National Heart, Lung, and Blood Institute. [date of access 2024 October 13]. Available from: https://www.nhlbi.nih.gov/events/2004/cardio-renal-connections-heart-failure-and-cardiovascular-diseasejRangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation. 2019;139:840-878. DOI: https://doi.org/10.1161/CIR.0000000000000664Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation. 2019;139:840-878. DOI: https://doi.org/10.1161/CIR.0000000000000664Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67. DOI: https://doi.org/10.1016/j.jacc.2003.07.031Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67. DOI: https://doi.org/10.1016/j.jacc.2003.07.031House AA, Anand I, Bellomo R. Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation. 2010;25 (5):1416-1420. DOI: https://doi.org/10.1093/ndt/gfq136House AA, Anand I, Bellomo R. Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation. 2010;25 (5):1416-1420. DOI: https://doi.org/10.1093/ndt/gfq136Ronco C, Bellomo R, McCullough P. Cardiorenal Syndrome: Pathophysiology and Recent Advances in Treatment. Nature Reviews Nephrology. 2023;19(5):311-325.Ronco C, Bellomo R, McCullough P. Cardiorenal Syndrome: Pathophysiology and Recent Advances in Treatment. Nature Reviews Nephrology. 2023;19(5):311-325.Суджаева О.А. Диагностика повреждения почек у кардиологических и кардиохирургических пациентов: современное состояние проблемы. Лечебное дело. 2021;1(76):56-65.Sudzhaeva OA. Diagnostics of kidney damage in cardiac and cardiac surgical patients: current state of the problem. General Medicine. 2021;1(76):56-65. (In Russ.).Spencer LJ, Degu A, Kalkidan HA, Solomon MA, Cristiana A, Nooshin A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990– 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. DOI: https://doi.org/10.1016/S0140-6736(18)32279-7Spencer LJ, Degu A, Kalkidan HA, Solomon MA, Cristiana A, Nooshin A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990– 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. DOI: https://doi.org/10.1016/S0140-6736(18)32279-7De Vecchis R, Baldi C. Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag. 2014;10:949-961. DOI: https://doi.org/10.2147/TCRM.S63255De Vecchis R, Baldi C. Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag. 2014;10:949-961. DOI: https://doi.org/10.2147/TCRM.S63255Braam B, Cupples WA, Joles JA, Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev. 2012;17(2):161-175. DOI: https://doi.org/10.1007/s10741-011-9246-2Braam B, Cupples WA, Joles JA, Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev. 2012;17(2):161-175. DOI: https://doi.org/10.1007/s10741-011-9246-2Iyngkaran P, Schneider H, Devarajan P, Anavekar N, Krum H, Ronco C. Cardio-renal syndrome: new perspective in diagnostics. Semin Nephrol. 2012;32(1):3-17. DOI: https://doi.org/10.1016/j.semnephrol.2011.11.002Iyngkaran P, Schneider H, Devarajan P, Anavekar N, Krum H, Ronco C. Cardio-renal syndrome: new perspective in diagnostics. Semin Nephrol. 2012;32(1):3-17. DOI: https://doi.org/10.1016/j.semnephrol.2011.11.002Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-269. DOI: https://doi.org/10.1056/nejmoa051530Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-269. DOI: https://doi.org/10.1056/nejmoa051530Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268-1274. DOI: https://doi.org/10.1016/j.jacc.2007.08.072Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268-1274. DOI: https://doi.org/10.1016/j.jacc.2007.08.072Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, et al. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018;43(5):1437-1450. DOI: https://doi.org/10.1159/000493657Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, et al. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018;43(5):1437-1450. DOI: https://doi.org/10.1159/000493657Ostraga M, Gierlotka MJ, Stonka G, Nadziakiewicz P, Gasior M. Clinical characteristics, treatment, and prognosis of patients with ischemic and nonischemic acute severe heart failure. Analysis of data from the COMMIT-AHF registry. Pol Arch Intern Med. 2017;127(5):328-335. DOI: https://doi.org/10.20452/pamw.3996Ostraga M, Gierlotka MJ, Stonka G, Nadziakiewicz P, Gasior M. Clinical characteristics, treatment, and prognosis of patients with ischemic and nonischemic acute severe heart failure. Analysis of data from the COMMIT-AHF registry. Pol Arch Intern Med. 2017;127(5):328-335. DOI: https://doi.org/10.20452/pamw.3996Bishara B, Abu-Saleh N, Awad H, Goltsman I, Ramadan R, Khamaysi I, et al. Pneumoperitoneum aggravates renal function in cases of decompensated but not compensated experimental congestive heart failure: role of nitric oxide. J Urol. 2011;186(1):310-317. DOI: https://doi.org/10.1016/j.juro.2011.03.040Bishara B, Abu-Saleh N, Awad H, Goltsman I, Ramadan R, Khamaysi I, et al. Pneumoperitoneum aggravates renal function in cases of decompensated but not compensated experimental congestive heart failure: role of nitric oxide. J Urol. 2011;186(1):310-317. DOI: https://doi.org/10.1016/j.juro.2011.03.040Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol. 2011;22(4):615-621. DOI: https://doi.org/10.1681/asn.2010121222Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol. 2011;22(4):615-621. DOI: https://doi.org/10.1681/asn.2010121222Lazzarini V, Bettari L, Bugatti S, Carubelli V, Lombardi C, et al. Can we prevent or treat renal dysfunction in acute heart failure? Heart Fail Rev. 2012;17(2):291-303. DOI: https://doi.org/10.1007/s10741-011-9253-3Lazzarini V, Bettari L, Bugatti S, Carubelli V, Lombardi C, et al. Can we prevent or treat renal dysfunction in acute heart failure? Heart Fail Rev. 2012;17(2):291-303. DOI: https://doi.org/10.1007/s10741-011-9253-3Медведева Е.А., Шиляева Н.В., Исхаков Э.Н., Щукин Ю.В. Кардиоренальный синдром при хронической сердечной недостаточности: патогенез, диагностика, прогноз и возможности терапии. Российский кардиологический журнал. 2017;(1):136-141.Medvedeva EA, Shilyaeva NV, Iskhakov EN, Schukin YuV. Cardiorenal syndrome in chronic heart failure: pathogenesis, diagnostics, prognosis and opportunities for treatment. Russian Journal of Cardiology. 2017;(1):136-141. (In Russ.).Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74(2):100-107. DOI: https://doi.org/10.1080/00015385.2018.1455947Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74(2):100-107. DOI: https://doi.org/10.1080/00015385.2018.1455947Резник Е.В., Никитин И.Г. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (Часть 1): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019;1(45):5-22.Reznik EV, Nikitin IG. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (Part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019;1(45):5-22. (In Russ.).Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome. Cardiology Research. 2020;11(2):76-88. DOI: https://doi.org/10.14740/cr955Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome. Cardiology Research. 2020;11(2):76-88. DOI: https://doi.org/10.14740/cr955Pullen AB, Jadapalli JK, Rhourri-Frih B, et al. Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease. Heart Fail Rev. 2020; 25:381-391. DOI: https://doi.org/10.1007/s10741-019-09817-xPullen AB, Jadapalli JK, Rhourri-Frih B, et al. Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease. Heart Fail Rev. 2020; 25:381-391. DOI: https://doi.org/10.1007/s10741-019-09817-xKumar U, Wettersten N, Garimella PS. Cardiorenal Syndrome: Pathophysiology. Cardiol Clin. 2019;37(3):251-265. DOI: https://doi.org/10.1016/j.ccl.2019.04.001Kumar U, Wettersten N, Garimella PS. Cardiorenal Syndrome: Pathophysiology. Cardiol Clin. 2019;37(3):251-265. DOI: https://doi.org/10.1016/j.ccl.2019.04.001Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314.Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;15:543-550. DOI: https://doi.org/10.1016/s0140-6736(09)61378-7Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;15:543-550. DOI: https://doi.org/10.1016/s0140-6736(09)61378-7Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813-1821. DOI: https://doi.org/10.1681/asn.2008121270Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813-1821. DOI: https://doi.org/10.1681/asn.2008121270Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226-1234. DOI: https://doi.org/10.1093/aje/kwn033Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226-1234. DOI: https://doi.org/10.1093/aje/kwn033Dutta A, Saha S, Bahl A, Mittal A, Basak T. A comprehensive review of acute cardio-renal syndrome: need for novel biomarkers. Front Pharmacol. 2023 May 23;14:1152055. DOI: https://doi.org/10.3389/fphar.2023.1152055Dutta A, Saha S, Bahl A, Mittal A, Basak T. A comprehensive review of acute cardio-renal syndrome: need for novel biomarkers. Front Pharmacol. 2023 May 23;14:1152055. DOI: https://doi.org/10.3389/fphar.2023.1152055Amsalem Y, Garty M, Schwartz R, Sandach A, Behar S, Caspi A, et al. Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. Eur Heart J. 2008;29(8):1029-1036. DOI: https://doi.org/10.1093/eurheartj/ehn102Amsalem Y, Garty M, Schwartz R, Sandach A, Behar S, Caspi A, et al. Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. Eur Heart J. 2008;29(8):1029-1036. DOI: https://doi.org/10.1093/eurheartj/ehn102Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009;20(3):672-679. DOI: https://doi.org/10.1681/asn.2008070669Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009;20(3):672-679. DOI: https://doi.org/10.1681/asn.2008070669Мельник А.А. Кардиоренальный синдром: диагностика и лечение. Почки. 2017;1(6):2-14.Melnik AA. Cardiorenal syndrome: diagnostics and treatment. Kidneys. 2017;1(6):2-14. (In Russ.).Махиева А.Т., Мамбетова А.М. Фетуин А – маркер оценки риска развития минерально-костных нарушений и формирования сердечно-сосудистой кальцификации у больных хронической болезнью почек 5Д стадии. Нефрология. 2022;26(4):105-109.Makhieva AT, Mambetova AM. Fetuin A – a marker for assessing the risk of developing mineral-bone disorders and the formation of cardiovascular calcification in patients with chronic kidney disease stage 5D. Nephrology. 2022;26(4):105-109. (In Russ.). DOI: https://doi.org/10.36485/1561-6274-2022-26-4-105-109Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99-111. DOI: https://doi.org/10.1038/nrneph.2012.279Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99-111. DOI: https://doi.org/10.1038/nrneph.2012.279Takada T, Kodera Y, Matsubara M, Kawashima Y, Maeda T. Serum monomeric α2-macroglobulin as a clinical biomarker in diabetes. Atherosclerosis. 2013;228:270-276.Takada T, Kodera Y, Matsubara M, Kawashima Y, Maeda T. Serum monomeric α2-macroglobulin as a clinical biomarker in diabetes. Atherosclerosis. 2013;228:270-276.Annapoorani P, Dhandapany PS, Sadayappan S, Ramasamy S, Rathinavel A. Cardiac isoform of alpha-2 macroglobulin — a new biomarker for myocardial infarcted diabetic patients. Atherosclerosis. 2006;186:173-176.Annapoorani P, Dhandapany PS, Sadayappan S, Ramasamy S, Rathinavel A. Cardiac isoform of alpha-2 macroglobulin — a new biomarker for myocardial infarcted diabetic patients. Atherosclerosis. 2006;186:173-176.McCallum W, Testani JM. Updates in Cardiorenal Syndrome. Med Clin North Am. 2023 Jul;107(4):763-780. DOI: https://doi.org/10.1016/j.mcna.2023.03.011McCallum W, Testani JM. Updates in Cardiorenal Syndrome. Med Clin North Am. 2023 Jul;107(4):763-780. DOI: https://doi.org/10.1016/j.mcna.2023.03.011Зырянов С.К., Ушкалова Е.А. Сравнительный фармакоэкономический анализ лекарственной терапии больных с хронической сердечной недостаточностью после декомпенсации. Российский кардиологический журнал. 2020;25(1):65-71. DOI: https://doi.org/10.15829/1560-4071-2020-1-3690Zyryanov SK, Ushkalova EA. Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure. Russian Journal of Cardiology. 2020;25(1):65-71. (In Russ.) DOI: https://doi.org/10.15829/1560-4071-2020-1-3690Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Клинические рекомендации ОССН-РКО-РНМОТ. Кардиология. 2018;58(S6):8-158. DOI: https://doi.org/10.18087/cardio.2475Mareev VYu, Fomin IV, Ageev FT, Begrambekova YuL, Vasyuk YuA, Garganeeva AA, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian scientific medical society of internal medicine guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(S6):8-158. (In Russ.). DOI: https://doi.org/10.18087/cardio.2475Salleck D, John S. Das Cardiorenal syndrome. Med Klin Intensivmed Notfmed. 2019;114(5):439-443. DOI: https://doi.org/10.1007/s00063-017-0346-1Salleck D, John S. Das Cardiorenal syndrome. Med Klin Intensivmed Notfmed. 2019;114(5):439-443. DOI: https://doi.org/10.1007/s00063-017-0346-1Jujo K, Saito K, Ishida I. Diuretic Strategies in Cardiorenal Syndrome: A Systematic Review. ESC Heart Failure. 2023;10(2):789-802.Jujo K, Saito K, Ishida I. Diuretic Strategies in Cardiorenal Syndrome: A Systematic Review. ESC Heart Failure. 2023;10(2):789-802.Heine GH, Rogacev KS. Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease. Deutsche medizinische Wochenschrift. 2019;144(24):1714-1720. DOI: https://doi.org/10.1055/a-0887-0792Heine GH, Rogacev KS. Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease. Deutsche medizinische Wochenschrift. 2019;144(24):1714-1720. DOI: https://doi.org/10.1055/a-0887-0792Chitturi C, Novak JE. Diuretics in the Management of Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018;25(5):425-433. DOI: https://doi.org/10.1053/j.ackd.2018.08.008Chitturi C, Novak JE. Diuretics in the Management of Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018;25(5):425-433. DOI: https://doi.org/10.1053/j.ackd.2018.08.008Brandenburg V, Heine GH. The Cardiorenal Syndrome. Deutsche medizinische Wochenschrift. 2019;144(6):382-386. DOI: https://doi.org/10.1055/a-0661-4456Brandenburg V, Heine GH. The Cardiorenal Syndrome. Deutsche medizinische Wochenschrift. 2019;144(6):382-386. DOI: https://doi.org/10.1055/a-0661-4456Wettersten N, Maisel AS, Cruz DN. Toward Precision Medicine in the Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018 Sep;25(5):418-424. DOI: https://doi.org/10.1053/j.ackd.2018.08.017Wettersten N, Maisel AS, Cruz DN. Toward Precision Medicine in the Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018 Sep;25(5):418-424. DOI: https://doi.org/10.1053/j.ackd.2018.08.017

The authors declare that there are no conflicts of interest present.